Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis

Journal of Neurology

Volumn 252, Issue SUPPL. 5, 2005, Pages

  Ziemssen, Tjalf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Inflammation; Multiple sclerosis; Neurodegeneration; Neuroprotection; Treatment

Indexed keywords

ALEMTUZUMAB; ALPHA4 INTEGRIN; ANTIINFLAMMATORY AGENT; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; LENERCEPT; LEUKEMIA INHIBITORY FACTOR; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; NEURITE PROMOTING FACTOR 2; PROTEIN ANTIBODY; SOMATOMEDIN B; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; AXONAL INJURY; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DEMYELINATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE REGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REMYELINIZATION; T LYMPHOCYTE; TARGET ORGAN;

ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; TIME FACTORS;

EID: 27444438215     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-5007-2     Document Type: Conference Paper

References (42)

1. Arredondo LR, Deng C, Ratts RB, et al. (2001) Role of nerve growth factor in experimental autoimmune encephalomyelitis. Eur J Immunol 31:625-633
2. Besser M, Wank R (1999) Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162:6303-6306
3. Bitsch A, Schuchardt J, Bunkowski S, et al. (2000) Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123:1174-1183
4. Bo L, Vedeler CA, Nyland H, et al. (2003) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 9:323-331
5. Braun A, Lommatzsch M, Mannsfeldt A, et al. (1999) Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 21:537-546
6. Brundula V, Rewcastle NB, Metz LM, et al. (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-1308
7. Butzkueven H, Zhang JG, Soilu-Hanninen M, et al. (2002) LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8:613-619
8. Cannella B, Hoban CJ, Gao YL, et al. (1998) The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc Nat Acad Sci USA 95:10100-10105
9. Cannella B, Pitt D, Capello E, Raine CS (2000) Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am J Pathol 157:933-943
10. Chen M, Valenzuela RM, Dhib-Jalbut S (2003) Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 215:37-44
11. Chitnis T, Imitola J, Khoury SJ (2005) Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord 5:11-26
12. Coles AJ, Wing MG, Molyneux P, et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296-304
13. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221-1231
14. Filippi M, Bozzali M, Rovaris M, et al. (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126:433-437
15. Flügel A, Matsumuro K, Neumann H, et al. (2001) Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 31:11-22
16. Giuliani F, Yong VW (2003) Immune-mediated neurodegeneration and neuroprotection in MS. Int MS J 10:122-130
17. Gravel C, Gotz R, Lorrain A, Sendtner M (1997) Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat Med 3:765-770
18. Grigoriadis N, Ben-Hur T, Karussis D, Milonas I (2004) Axonal damage in multiple sclerosis: a complex issue in a complex disease. Clin Neurol Neurosurg 106:211-217
19. Kerschensteiner M, Gallmeier E, Behrens L, et al. (1999) Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865-870
20. Kerschensteiner M, Stadelmann C, Dechant G, et al. (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53:292-304
21. Kieseier BC, Hartung HP (2003) Multiple paradigm shifts in multiple sclerosis. Curr Opin Neurol 16:247-252
22. Korner H, Goodsall AL, Lemckert FA, et al. (1995) Unimpaired autoreactive T cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci 92:11066-11070
23. Korner H, Lemckert FA, Chaudhri G, et al. (1997) Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol 27:1973-1981
24. Liu X, Linnington C, Webster HD, et al. (1997) Insulin-like growth factor-I treatment reduces immune cell responses in acute non-demyelinative experimental autoimmune encephalomyelitis. J Neurosci Res 47:531-538
25. Lovett-Racke AE, Bittner P, Cross AH, et al. (1998) Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-I) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest 101:1797-1804
26. Metz LM, Zhang Y, Yeung M, et al. (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55:756
27. Moalem G, Leibowitz-Amit R, Yoles E, et al. (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5:49-55
28. Neuhaus O, Farina C, Wekerle H, Hohlfeld R (2001) Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702-708
29. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343:938-952
30. Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389-400
31. Popovic N, Schubart A, Goetz BD, et al. (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51:215-223
32. Schwartz M, Kipnis J (2005) Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 233:163-166
33. Stadelmann C, Kerschensteiner M, Misgeld T, et al. (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125:75-85
34. Steinman L (2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2:762-764
35. Teismann P, Schulz JB (2004) Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318:149-161
36. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465
37. Tikka T, Fiebich BL, Goldsteins G, et al. (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21:2580-2588
38. Villoslada P, Hauser SL, Bartke I, et al. (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 191:1799-1806
39. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16:183-200
40. Ziemssen T, Kumpfel T, Klinkert WE, et al. (2002) Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125:2381-2391
41. Ziemssen T (2004) Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. Adv Exp Med Biol 541:111-134
42. Ziemssen T, Ziemssen F (2005) The role of the humanal immune system in multiple sclerosis (MS) and its animal model experimental automimmune encephalomyelitis (EAE). Autoimmun Rev 4:460-467